difficulties. There are often multiple ID providers with inadequate time to properly orchestrate follow-up. There are undefined checkpoints and triaging in the department’s scheduling policies. Interventions involved reformatting the ID sign-off template and clarifying the roles of providers in the transitions-of-care process. Analysis after 6 months of implementation revealed improvement of communication among teams, decline in improper sign-off by 13% and decrease in inappropriate antibiotic prescription errors by 2%

Conclusion. This study demonstrates that well-designed sign-off templates can help with effective communication of the final treatment plan among providers and possibly improve patient outcomes. The target goal is to reduce the number of improper sign-offs by 50% within 1 year.

![Figure 1. Current Transfer of Care](image1)

### Figure 1. Current Transfer of Care

- **Figure Caption:** Patient transfer process with various departments and stakeholders involved.
- **Legend:** IMC = Inpatient Medical Consult, OOR = Outpatient Office Follow-up, OPD = Outpatient Department, IP = Inpatient Department.
- **Key Points:**
  - IMC determines agency for OOR.
  - OOR chooses agency for implementation per plan.
  - Inpatient team needs to ensure all sign-offs are complete per plan.
  - Outpatient team is followed up by OOR.
  - Telephone follow-up is possible by IMC.

### Table 1: Baseline and Study Period Comparison

|                         | Baseline Period | Study Period | P value |
|-------------------------|-----------------|--------------|---------|
| Patients (n)            | 148             | 148          |         |
| Average length of stay  | 6.7             | 7.1          | 0.54    |
| Case mix index          | 1.16            | 1.23         | 0.46    |
| Average days on antibiotics | 5.9          | 6.2          | 0.47    |
| Average drug cost       | $484            | $496         | 0.15    |
| Readmission %           | 22.2            | 17.8         | 0.38    |
| Deaths                  | 3               | 3            | 1       |

Conclusion. Baseline period had 148 inpatient stays and study period had 148 inpatient stays. Despite similar case mix index in both groups, there was no statistical difference between the clinical outcomes. Results are shown in Table 1.

![Figure 2. Root Cause Analysis](image2)

### Figure 2. Root Cause Analysis

- **Figure Caption:** Root cause analysis flowchart for inappropriate ID follow-ups.
- **Legend:**
  - **Provider:** Patient lives far from Mayo
  - **Multiple teams:** Variable literacy, Social or financial difficulties
  - **Patient:** Policies
  - **Inappropriate ID follow-ups:** Undefined “checkpoints” or triaging prior to scheduling

### Table 2: Baseline and Study Period Comparison

|                         | Baseline Period | Study Period | P value |
|-------------------------|-----------------|--------------|---------|
| Patients (n)            | 148             | 148          |         |
| Average length of stay  | 6.7             | 7.1          | 0.54    |
| Case mix index          | 1.16            | 1.23         | 0.46    |
| Average days on antibiotics | 5.9          | 6.2          | 0.47    |
| Average drug cost       | $484            | $496         | 0.15    |
| Readmission %           | 22.2            | 17.8         | 0.38    |
| Deaths                  | 3               | 3            | 1       |

Conclusion. Tele-ID at our hospitals was noninferior to in-person ID consults. An integrated computer system, nursing support, and daily follow-up are key components of a successful Tele-ID program.

### Disclosures. All authors: No reported disclosures.

1639. Efficacy of Voriconazole Prophylaxis Followed by Therapeutic Liposomal Amphotericin B for the Treatment of Marine Pulmonary Aspergillosis Caused by Azole-Resistant Aspergillus fumigatus Strains

Jon Olson, MS, Matthew Slarve, BS and Jill Adler-Moore, PhD, Biological Sciences, California State Polytechnic University, Pomona, California

Session: 168. Novel Therapies for Superbugs

Friday, October 5, 2018: 2:00 PM

Background. Antifungal treatment for pulmonary aspergillosis is more difficult if the fungal strain causing the infection is azole resistant. To investigate this problem, we used a murine model of pulmonary aspergillosis caused by azole-resistant Aspergillus fumigatus strains V29 and V45, and compared treatment with voriconazole (Vf, oral 40 mg/kg, bd) or liposomal amphotericin B (L-AmB, 5 mg/kg, IV) used alone or in combination.

### Methods.

Mice (n = 14/group) were immunosuppressed with 24 mg/kg triamcinolone acetonide, IP, d-3, d-1, and d+1 relative to fungal challenge (d0). For 2 groups, Vf was given prophylactically (proph) d-3, d-2, d-1 followed by L-AmB or buffer, d+1, d+2, and d+3. The other groups were given Vf, L-AmB, Vf+L-AmB, or buffer d+1, d+2, and d+3. On d0, mice were given 1.3 to 1.6 × 10⁷ A. fumigatus spores intranasally (Vf MIC = 64 μg/mL, V29; Vf MIC = 8 μg/mL, V45). On d+3, lungs were collected from 7 mice/group and fungal burden determined by plating for colony forming units; 7 mice/group were then monitored for morbidity to d+21.

### Results.

Optimum treatment was observed when Vf was given prophyl, followed by L-AmB post-challenge (Vf/L-AmB), with better survival (100%) for both fungal strains vs. buffer or Vf post-challenge (P ≤ 0.04); for V29, significantly better survival was also seen with Vf/L-AmB vs. L-AmB or Vf+L-AmB post-challenge (P ≤ 0.01). For strain V45, lung fungal burden was significantly lower for Vf/L-AmB versus all other treatments (P ≤ 0.04), while for strain V29, fungal burden was lower for the Vf/L-AmB and L-AmB post-challenge groups versus the other groups, but the differences were not significant. Notably, although the lung fungal burden with Vf proph and Vf postchallenge were both similar to the buffer control, Vf proph yielded significantly better survival than Vf post-challenge (P ≤ 0.001).

### Conclusion.

These preclinical observations demonstrate that combining L-AmB with Vf for the postchallenge treatment of pulmonary aspergillosis caused by azole-resistant strains is not an effective therapeutic option. However, the results do show that Vf proph, but not Vf postchallenge, can have some limited antifungal activity, and can significantly enhance the antifungal effects of post-challenge L-AmB. This regimen could be considered in areas where there is a high incidence of azole-resistant A. fumigatus.

### Disclosures. All authors: No reported disclosures.